Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

This study has been terminated.
(See termination reason in detailed description.)
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01208233
First received: September 22, 2010
Last updated: January 22, 2016
Last verified: January 2016
  Purpose
The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also explore the relationship between PF-03049423 concentration and blood pressure.

Condition Intervention Phase
Ischemic Stroke
Drug: PF-03049423
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of Pf-03049423 In Subjects With Ischemic Stroke

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Number of Participants With Any Abnormal Laboratory Test Results (Part 1* and 2) [ Time Frame: Day 1 (Baseline) up to Day 90 ] [ Designated as safety issue: Yes ]
    The total number of participants with laboratory test abnormalities (without regard to baseline abnormality) was assessed. *This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.

  • Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern (Part 1* and 2) [ Time Frame: Day 1 (Baseline) up to follow-up (28 days after Day 90) ] [ Designated as safety issue: Yes ]
    Vital signs included blood pressure (BP; supine, sitting and standing) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: systolic BP (SBP) greater than or equal to (>=) 30 or 50 millimeters of mercury (mm Hg) change from grand baseline in same posture, systolic less than (<) 90 mm Hg; diastolic BP (DBP) >=20 mm Hg change from grand baseline in same posture, diastolic <50 mm Hg; 2), pulse rate (supine, sitting and standing): <40 or greater than (>) 120 beats per minute (bpm); Standing: <40 or >140 bpm. *This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.

  • Number of Participants With Electrocardiograms (ECGs) Data Met Criteria of Potential Clinical Concern (Part 1* and 2) [ Time Frame: Day 1 (Baseline) to Day 90 ] [ Designated as safety issue: Yes ]
    ECG criteria of potential clinical concern were 1), PR interval: >=300 milliseconds (msec); >=25% increase when baseline >200 msec; or increase >=50% when baseline <=200 msec; 2), QRS interval: >=140 msec; >=50% increase from baseline; 3), QT interval: >=500 msec, QTc interval using Fridericia's formula (QTcF interval): absolute value >=450 - <480 msec, >=480-<500 msec, >=500 msec; absolute change 30 - <60, >=60 msec. *This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.

  • Number of Participants With Significant Change in Physical Examination Findings (Part 1* and 2) [ Time Frame: Day 1 (Baseline) up to Day 90 ] [ Designated as safety issue: Yes ]
    The complete physical examination included examination of the skin, eyes, ears, throat, neck, cardiac, respiratory, gastrointestinal, and musculoskeletal systems. The limited physical examination included examination of the cardiac, respiratory, gastrointestinal, and musculoskeletal systems. *This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.

  • Number of Participants With Significant Change in Neurological Examination Findings (Part 1* and 2) [ Time Frame: Day 1 (Baseline) up to Day 90 ] [ Designated as safety issue: Yes ]
    The complete neurological examination included an assessment of the motor, sensory, cranial nerves, reflexes, mental status and associated motor functions. The limited neurological exam could examine the same categories of neurologic assessments as the full examination, but would differ by the depth in the examination. The examination was required to be done to the extent needed to assess the participant for any potential changes in neurological status, as determined by the Investigator, but had to always include an assessment of motor, vision and hearing. *This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.

  • Number of Participants With Suicidal Behavior and/or Ideation as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) (Part 1* and 2) [ Time Frame: Day 7 (Baseline) up to follow up (28 days after Day 90) ] [ Designated as safety issue: Yes ]
    Data were mapped to Columbia-Classification Algorithm of Suicide Assessment (C-CASA) event codes. C-SSRS assessed if participant experienced: completed suicide (Code 1), suicide attempt (Code 2) (Response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (Code 3) ("Yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), suicidal ideation (Code 4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act/some intent to act without specific plan or with specific plan and intent), self-injurious behavior, no suicidal intent (Code 7) ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior"). Number of participants with "Yes" response for any of above mentioned categories was assessed. *This was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for it were not reported separately, Part 1 and 2 data were reported together.

  • Percentage of Participants With Modified Rankin Scale (mRS) Less Than or Equal to (<=2) at Day 90 (Part 2) [ Time Frame: Day 90 ] [ Designated as safety issue: No ]
    The mRS is a 6-point scale of functional recovery. The scale grades participants as having no symptoms (0), minor symptoms (1), minor handicap (2), moderate handicap (3), moderately severe handicap (4), severe handicap (5), or death (6).


Secondary Outcome Measures:
  • Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Paretic Hand (Part 2) [ Time Frame: Day 1 (Baseline), Day 90 ] [ Designated as safety issue: No ]
    The B&B test is a measure of manual dexterity. The B&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.

  • Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Paretic to Non-paretic Hand Ratio (Part 2) [ Time Frame: Day 1 (Baseline), Day 90 ] [ Designated as safety issue: No ]
    The B&B test is a measure of manual dexterity. The B&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.

  • Change From Baseline in Hand Grip Strength Test at Day 90 for Paretic and Non-paretic Hands (Part 2) [ Time Frame: Day 1 (Baseline), Day 90 ] [ Designated as safety issue: No ]
    The Hand Grip Strength Test measures the maximum isometric strength of the hand and forearm muscles. The participant was required to squeeze the dynamometer with maximum isometric effort while sitting with shoulder adducted and neutrally roated, elbow flexed at 90 degrees and the forearm in neutral position and wrist between 0 to 30 degrees dorsiflexion and a 0 to 15 degrees ulnar deviation. The participant performed this task 3 times with each hand, starting with the non-paretic hand. The performance measure for this task was the average score measured in pounds of pressure exerted.

  • Change From Baseline in Hand Grip Strength Test at Day 90 for Paretic to Non-paretic Hand Ratio (Part 2) [ Time Frame: Day 1 (Baseline), Day 90 ] [ Designated as safety issue: No ]
    The Hand Grip Strength Test measures the maximum isometric strength of the hand and forearm muscles. The participant was required to squeeze the dynamometer with maximum isometric effort while sitting with shoulder adducted and neutrally roated, elbow flexed at 90 degrees and the forearm in neutral position and wrist between 0 to 30 degrees dorsiflexion and a 0 to 15 degrees ulnar deviation. The participant performed this task 3 times with each hand, starting with the non-paretic hand. The performance measure for this task was the average score measured in pounds of pressure exerted.

  • Percentage of Participants With mRS (0-1) at Day 90 (Part 2) [ Time Frame: Day 90 ] [ Designated as safety issue: No ]
    The mRS is a 6-point scale of functional recovery. The scale grades participants as having no symptoms (0), minor symptoms (1), minor handicap (2), moderate handicap (3), moderately severe handicap (4), severe handicap (5), or death (6).

  • Percentage of Participants With National Institutes of Health Stroke Scale (NIHSS) (0-1) at Day 90 (Part 2) [ Time Frame: Day 90 ] [ Designated as safety issue: Yes ]
    The NIHSS is a graded 11-item neurological examination rating speech and language, cognition, visual field deficits, motor and sensory impairments and ataxia used for the clinical assessment of acute stroke therapy. The maximum total score is 42 in a participant with a severe neurological deficit; the minimum score is 0 in a participant without gross neurological deficits.

  • Change From Baseline in NIHSS at Day 90 (Part 2) [ Time Frame: Day 1 (Baseline), Day 90 ] [ Designated as safety issue: Yes ]
    The NIHSS is a graded 11-item neurological examination rating speech and language, cognition, visual field deficits, motor and sensory impairments and ataxia used for the clinical assessment of acute stroke therapy. The maximum total score is 42 in a participant with a severe neurological deficit; the minimum score is 0 in a participant without gross neurological deficits.

  • Percentage of Participants With Barthel Index (BI) >= 95 and BI =100 at Day 90 (Part 2) [ Time Frame: Day 90 ] [ Designated as safety issue: No ]
    The BI is an index of independence to score the ability of a participant with a neuromuscular or musculoskeletal disorder to care for him or herself. The index rates a participant's ability on the following 10 activities: feeding, moving from wheelchair to bed, personal toilet, getting on and off toilet, bathing self, walking on level surface, ascending and descending stairs, dressing, controlling bowels and controlling bladder. The maximum total score is 100 in a participant without functional impairment; the minimum score is 0 in a participant with major functional impairment.

  • BI at Day 90 (Part 2) [ Time Frame: Day 90 ] [ Designated as safety issue: No ]
    The BI is an index of independence to score the ability of a participant with a neuromuscular or musculoskeletal disorder to care for him or herself. The index rates a participant's ability on the following 10 activities: feeding, moving from wheelchair to bed, personal toilet, getting on and off toilet, bathing self, walking on level surface, ascending and descending stairs, dressing, controlling bowels and controlling bladder. The maximum total score is 100 in a participant without functional impairment; the minimum score is 0 in a participant with major functional impairment.

  • Domains of Interest: Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Coding Sub Test at Day 90 (Part 2) [ Time Frame: Day 1 (Baseline), Day 90 ] [ Designated as safety issue: No ]
    The test uses a reference key, the participant had 90 seconds to pair specific numbers with given geometric figures. Responses could be written or oral. The performance measure for this task was the total number of correct responses.

  • Domains of Interest: Change From Baseline in RBANS Naming Sub Test at Day 90 (Part 2) [ Time Frame: Day 1 (Baseline), Day 90 ] [ Designated as safety issue: No ]
    This test requires the participant to name 10 objects drawn in ink. The tester asked the participant to identify the picture. The participant had 20 seconds to respond to each picture presented. The performance measure was the number of objects named correctly.

  • Domains of Interest: Change From Baseline in Line Cancellation Test [(L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%)] at Day 90 (Part 2) [ Time Frame: Day 1 (Baseline), Day 90 ] [ Designated as safety issue: No ]
    The participant was presented with a page that had lines placed across the page. The participant was required to cross out all the lines on the page using their non-paretic hand after the tester had demonstrated what was required by crossing out the center line. The performance measure for this task was the total number of omissions made expressed as a percentage of the total number of items in the test. The test contains 4 variables: (L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%, and (L-R)/(L+R), where L = number of lines crossed on the left side of the paper; R = number of lines crossed on the right side of the paper.

  • Domains of Interest: Change From Baseline in Line Cancellation Test at Day 90 [(L-R)/(L+R)] (Part 2) [ Time Frame: Day 1 (Baseline), Day 90 ] [ Designated as safety issue: No ]
    The participant was presented with a page that had lines placed across the page. The participant was required to cross out all the lines on the page using their non-paretic hand after the tester had demonstrated what was required by crossing out the center line. The performance measure for this task was the total number of omissions made expressed as a percentage of the total number of items in the test. The test contains 4 variables: (L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%, and (L-R)/(L+R), where L = number of lines crossed on the left side of the paper; R = number of lines crossed on the right side of the paper.

  • Domains of Interest: Change From Baseline in Recognition Memory Test at Day 90 (Part 2) [ Time Frame: Day 1 (Baseline), Day 90 ] [ Designated as safety issue: No ]
    This test assesses the ability to recognize pictures of objects. The participant was presented a series of pictures, a subset of which were the objects presented in the RBANS Naming Sub Test. After each picture was presented, the participant indicated either manually (ie, affirmative head nod) or verbally whether the picture was seen previously. The participant was given 5 seconds per picture to respond. The performance measure for this task was the total number of pictures correctly identified.

  • Gait Velocity Test at Day 90 (Part 2) [ Time Frame: Day 90 ] [ Designated as safety issue: No ]
    The 10-meter walk test requires a 20 meter straight path, with 5 meters for acceleration, 10 meters for steady state walking, and 5 meters for deceleration. Markers were placed at the 5 and 15 meter positions along the path. The participant began to walk "at a comfortable pace" at 1 end of the path, and continued walking until he/she reached the other end. The rater used a stopwatch to determine how much time it took for the participant to traverse the 10 meter center of the path, starting the stopwatch as soon as the participant's limb crossed the first marker and stopping the stopwatch as soon as the participant's limb crossed the second marker.

  • Plasma Concentrations of PF-03049423 (Part 1 and 2) [ Time Frame: Days 1, 2, 7, 14, 30, 60 and 90 ] [ Designated as safety issue: No ]
  • Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Non-paretic Hand (Part 2) [ Time Frame: Day 1 (Baseline), Day 90 ] [ Designated as safety issue: No ]
    The B&B test is a measure of manual dexterity. The B&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.


Other Outcome Measures:
  • All-cause Mortality (Part 2) [ Time Frame: The time began from the participant provided informed consent through 28 calendar days post last administration of investigational product. ] [ Designated as safety issue: Yes ]
    Deaths regardless causality were reported.

  • Mortality Directly Related to Stroke (Part 2) [ Time Frame: The time began from the participant provided informed consent through 28 calendar days post last administration of investigational product. ] [ Designated as safety issue: Yes ]
    Deaths caused by stroke were reported.

  • Number of Participants With Neuro-worsening (Part 2) [ Time Frame: Day 1 (Baseline) up to Day 90 ] [ Designated as safety issue: Yes ]
    NIHSS change of 4 points or greater.

  • Number of Participants With SBP <100 mm Hg or SBP Decline >=30 mm Hg From Immediate Pre-dose Measurement, With or Without Neuro-worsening (Defined as an NIHSS Increase of 4 Points or Greater) Within 2 Hours Post-dose (Part 2) [ Time Frame: Day 1 (Baseline) up to Day 14 ] [ Designated as safety issue: Yes ]
  • Treatment-emergent Adverse Events (AEs) Resulting in Discontinuation of Study Drug (Part 2) [ Time Frame: Day 1 (Baseline) up to follow-up (28 days after Day 90) ] [ Designated as safety issue: Yes ]
    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.


Enrollment: 181
Study Start Date: December 2010
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 mg PF-03049423 Drug: PF-03049423
1 mg of PF-03049423 daily for 90 days
Experimental: 3 mg of PF-03049423 Drug: PF-03049423
3 mg of PF-03049423 daily for 90 days
Experimental: 6 mg of PF-03049423 Drug: PF-03049423
6 mg of PF-03049423 daily for 90 days
Placebo Comparator: Placebo Other: Placebo
Placebo of PF-03049423 daily for 90 days

Detailed Description:
The interim analysis for the POC study A9541004 demonstrated futility, and the study was stopped on the 6th of November 2013. There were no signals of serious safety concern.
  Eligibility

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of ischemic stroke with an onset within 72 hours prior to start of study agent administration, male or female.
  • Supratentorial ischemic stroke involving the cortex documented by neurological exam and confirmed by MRI.
  • Stroke involving upper extremity.
  • Subjects who received thrombolytic therapy may be enrolled and the use of antiplatelet is acceptable.

Exclusion Criteria:

  • Any other severe acute or chronic medical or psychiatric condition besides the stroke.
  • Women of child bearing potential.
  • Uncontrolled hypertension.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01208233

  Hide Study Locations
Locations
United States, Alabama
Spain Rehabilitation Center
Birmingham, Alabama, United States, 35233
The Kirklin Clinic
Birmingham, Alabama, United States, 35233
University Hospital
Birmingham, Alabama, United States, 35294-3280
United States, Florida
Broward Health North
Deerfield Beach, Florida, United States, 33064
Neurologic Consultant, P.A.
Fort Lauderdale, Florida, United States, 33308
Fawcett Memorial Hospital
Port Charlotte, Florida, United States, 33952
Neurostudies, Inc.
Port Charlotte, Florida, United States, 33952
United States, Georgia
Jagdish Sidhpura M.D.
Columbus, Georgia, United States, 31901
Jose Canedo, M.D., West Georgia Neurology
Columbus, Georgia, United States, 31904
St. Francis Hospital
Columbus, Georgia, United States, 31904
Muscogee Manor & Rehabilitation Center
Columbus, Georgia, United States, 31907
Medical Research & Health Education Foundation, Inc.
Columbus, Georgia, United States, 31909
United States, Indiana
Parkview Hospital Randallia
Fort Wayne, Indiana, United States, 46805
Fort Wayne Neurological Center
Fort Wayne, Indiana, United States, 46845
Parkview Regional Medical Center
Fort Wayne, Indiana, United States, 46845
Parkview Research Center
Fort Wayne, Indiana, United States, 46845
Norwood Nursing Center
Huntington, Indiana, United States, 46750
United States, Massachusetts
Massachusetts General Hospital/Department of Neurology
Boston, Massachusetts, United States, 02114
Spaulding Rehabilitation Hospital
Boston, Massachusetts, United States, 02129
United States, Michigan
Wayne State University
Detroit, Michigan, United States, 48201
United States, Missouri
Barnes-Jewish Hospital
St. Louis, Missouri, United States, 63110
Rehabilitation Institute of St. Louis
St. Louis, Missouri, United States, 63110
United States, North Carolina
UNC HealthCare
Chapel Hill, North Carolina, United States, 27514
UNC Department of Neurology Stroke Division
Chapel Hill, North Carolina, United States, 27599-7025
United States, Oklahoma
Investigational Drug Services at OU Medical Center
Oklahoma City, Oklahoma, United States, 73104
Oklahoma University Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
OU Medical Center
Oklahoma City, Oklahoma, United States, 73104
OU Physicians Building
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Penn State Milton South Hershey Medical Center / Penn State College of Medicine
Hershey, Pennsylvania, United States, 17033
Penn State Hershey Rehabilitation Hospital
Hummelstown, Pennsylvania, United States, 17036
United States, Texas
The Methodist Hospital Neurological Institute
Houston, Texas, United States, 77030
The Methodist Hospital
Houston, Texas, United States, 77030
Bulgaria
Voennomeditsinska Akademia - MBAL- Pleven, Otdelenie po Nervni bolesti
Pleven, Bulgaria, 5800
MBAL Kaspela
Plovdiv, Bulgaria, 4002
MBALNP "Sveti Naum" EAD, Klinika za Intenzivno Lechenie na Nervni Bolesti
Sofia, Bulgaria, 1113
Vtora Mnogoprofilna Bolnitsa za Aktivno Lechenie, Otdelenie po Nevrologia
Sofia, Bulgaria, 1202
MBAL "Tokuda Bolnitsa", Otdelenie po nevrologiya
Sofia, Bulgaria, 1407
Universitetska mnogoprofilna bolnitsa za aktivno lechenie Aleksandrovska, Klinika po Nevrologia
Sofia, Bulgaria, 1431
UMBAL Tsaritsa Yoanna, Klinika po nevrologia
Sofia, Bulgaria, 1527
Canada, Alberta
Grey Nuns Community Hospital
Edmonton, Alberta, Canada, T6L 5X8
Czech Republic
Fakultni nemocnice u sv. Anny v Brne
Brno, Czech Republic, 65691
Fakultni nemocnice Plzen
Plzen - Lochotin, Czech Republic, 304 60
France
CHU Pellegrin
Bordeaux, France, 33076
CHU La Pitie Salpetriere
Paris Cedex 13, France, 75651
Germany
Klinikum Altenburger Land
Altenburg, Germany, 04600
Universitaetsklinikum Essen, Neurologische Klinik
Essen, Germany, 45122
Universitaetsklinikum Leipzig
Leipzig, Germany, 04103
Klinikum Rechts der Isar, Neurologische Klinik
Muenchen, Germany, 81675
Universitaetsklinikum Muenster
Muenster, Germany, 48149
Universitaet Regensburg
Regensburg, Germany, 93053
Hungary
Dr. Kennessey Albert Korhaz-Rendelointezet, Neurologiai Osztaly
Balassagyarmat, Hungary, 2660
Fovarosi Onkormanyzat Peterfy Sandor utcai Korhaz-Rendelointezet es Baleseti Kozpont/Neurologia
Budapest, Hungary, 1076
Semmelweis Egyetem AOK / Neurologiai Klinika
Budapest, Hungary, 1083
Honvedkorhaz-Allami Egeszsegugyi Kozpont, Ideggyogyaszati Osztaly
Budapest, Hungary, 1134
Orszagos Idegtudomanyi Intezet, Stroke-ambulancia
Budapest, Hungary, 1145
Petz Aladar Megyei Oktato Korhaz, Neurologiai Osztaly
Gyor, Hungary, 9024
India
KEM Hospital
Pune, Maharashtra, India, 411011
Max Super Speciality Hospital
New Delhi, India, 110017
Korea, Republic of
Seoul National University Bundang Hospital, Department of Neurology
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
Hallym University Sacred Heart Hospital, Department of Neurology
Anyang-si, Gyonggi-do, Korea, Republic of, 431-070
Chonnam National University Hospital, Department of Neurology
Gwangju, Korea, Republic of, 501-757
Inha University Hospital, Department of Neurology
Incheon, Korea, Republic of, 400-711
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Severance Hospital, Yonsei University College of Medicine, Department of Neurology
Seoul, Korea, Republic of, 120-752
Samsung Medical Center, Department of Neurology
Seoul, Korea, Republic of, 135710
Asan Medical Center, Department of Neurology
Seoul, Korea, Republic of, 138-736
Taiwan
Chang Gung Medical Foundation-Kaohsiung Chang Gung Memorial Hospital
Kaohsiung, Taiwan, 833
China Medical University Hospital
Taichung, Taiwan, 404
National Taiwan University Hospital
Taipei, Taiwan, 100
Chang Gung Medical Foundation-Linkou Branch
Taoyuan County, Taiwan, 333
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01208233     History of Changes
Other Study ID Numbers: A9541004  2010-021414-32 
Study First Received: September 22, 2010
Results First Received: February 19, 2015
Last Updated: January 22, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Phase 2 Ischemic stroke Safety and efficacy

Additional relevant MeSH terms:
Stroke
Ischemia
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia

ClinicalTrials.gov processed this record on September 29, 2016